TRANSLATE

The lupus Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lupus Hub cannot guarantee the accuracy of translated content. The lupus and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

The Lupus Hub
Brought to you by Scientific Education Support

The Lupus Hub is an independent medical education platform, supported through a grant from AstraZeneca. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders. 

View all

Now you can support HCPs in making informed decisions for their patients

Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.

Find out more

ACR Convergence 2023 abstracts: What’s hot in systemic lupus erythematosus and lupus nephritis?

By Haimanti Mandal

Share:

Nov 3, 2023

To help navigate the exciting content being presented at the American College of Rheumatology (ACR) annual meeting (ACR Convergence 2023), we have provided recommendations for the top abstracts to look out for in lupus.

 

Systemic lupus erythematosus

0597

Efficacy of anifrolumab in systemic lupus erythematosus by overall and organ-specific SLEDAI-2K improvements: Results from the randomized, placebo-controlled phase 3 long-term extension study

0608

Efficacy of cenerimod in patients with high IFN-1 gene expression signature and high anti-dsDNA antibody levels: Post-hoc analysis from a phase 2 study

1489

Treatment with upadacitinib in patients with systemic lupus erythematosus results in the inhibition of B-cell–related biomarkers: Analysis of the M19-130 (SLEek) phase 2 study

2328

Deucravacitinib, an oral, allosteric, tyrosine kinase 2 (TYK2) inhibitor, in patients with active systemic lupus erythematosus: Patient-reported outcomes in a phase 2 trial

2487

Phase 2 safety and efficacy of subcutaneous (s.c.) dose ianalumab (VAY736; Anti-BAFFR mAb) administered monthly over 28 Weeks in patients with systemic lupus erythematosus (SLE) of moderate-to-severe activity

2488

Efficacy and safety of ABBV-599 high dose (Elsubrutinib 60 mg and Upadacitinib 30 mg) and upadacitinib monotherapy for the treatment of systemic lupus erythematosus: A phase 2, double-blind, placebo-controlled trial

L13

An open-label, multicenter, phase 1/2 study to assess safety, efficacy and cellular kinetics of YTB323, a rapid manufacturing CAR-T Cell therapy targeting CD19 on B cells, for severe refractory systemic lupus erythematosus: Preliminary results

 

Lupus nephritis

0595

Renal involvement in patients with systemic lupus erythematosus treated with anifrolumab compared with placebo over a 4-year period

0782

Comparison of dual-immunosuppressive therapy with a voclosporin-based, triple-immunosuppressive regimen for lupus nephritis in the ALMS and AURORA 1 studies

0784

Kidney-related outcomes and steroid-sparing effects in patients with active lupus nephritis treated with obinutuzumab: A post hoc analysis of a phase 2 trial

ACR Convergence 2023 Abstracts

To download this document, click below.

Please indicate your level of agreement with the following statements:

The content was clear and easy to understand

The content addressed the learning objectives

The content was relevant to my practice

I will change my clinical practice as a result of this content

More about...

ACR Convergence 2023Lupus nephritisSystemic lupus erythematosus

Newsletter

Subscribe to get the best content delivered to your inbox